These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
546 related articles for article (PubMed ID: 30833002)
1. Immunotherapy for Head and Neck Cancer. Sim F; Leidner R; Bell RB Hematol Oncol Clin North Am; 2019 Apr; 33(2):301-321. PubMed ID: 30833002 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Head and Neck Cancer. Sim F; Leidner R; Bell RB Oral Maxillofac Surg Clin North Am; 2019 Feb; 31(1):85-100. PubMed ID: 30449528 [TBL] [Abstract][Full Text] [Related]
3. Immunology and Immunotherapy of Head and Neck Cancer. Ferris RL J Clin Oncol; 2015 Oct; 33(29):3293-304. PubMed ID: 26351330 [TBL] [Abstract][Full Text] [Related]
4. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Miyauchi S; Kim SS; Pang J; Gold KA; Gutkind JS; Califano JA; Mell LK; Cohen EEW; Sharabi AB Clin Cancer Res; 2019 Jul; 25(14):4211-4223. PubMed ID: 30814108 [TBL] [Abstract][Full Text] [Related]
5. Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma. Seliger B; Massa C; Yang B; Bethmann D; Kappler M; Eckert AW; Wickenhauser C Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987799 [TBL] [Abstract][Full Text] [Related]
6. Tumor immune microenvironment in head and neck cancers. Chen SMY; Krinsky AL; Woolaver RA; Wang X; Chen Z; Wang JH Mol Carcinog; 2020 Jul; 59(7):766-774. PubMed ID: 32017286 [TBL] [Abstract][Full Text] [Related]
7. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178 [TBL] [Abstract][Full Text] [Related]
8. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers. Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268 [TBL] [Abstract][Full Text] [Related]
9. [Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress]. Huang LL; Shi YK Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):641-647. PubMed ID: 31550852 [TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Mei Z; Huang J; Qiao B; Lam AK Int J Oral Sci; 2020 May; 12(1):16. PubMed ID: 32461587 [TBL] [Abstract][Full Text] [Related]
11. The biology of combination immunotherapy in recurrent metastatic head and neck cancer. Yuan X; Yi M; Zhang W; Xu L; Chu Q; Luo S; Wu K Int J Biochem Cell Biol; 2021 Jul; 136():106002. PubMed ID: 33962022 [TBL] [Abstract][Full Text] [Related]
12. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504 [TBL] [Abstract][Full Text] [Related]
13. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205 [TBL] [Abstract][Full Text] [Related]
14. Immune-scoring in head and neck squamous cell carcinoma: a scoping review. Zamani R; Rezaei N Expert Rev Clin Immunol; 2024 Aug; 20(8):1009-1017. PubMed ID: 37750738 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727 [TBL] [Abstract][Full Text] [Related]
16. Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment. Farlow JL; Brenner JC; Lei YL; Chinn SB Oral Oncol; 2021 Sep; 120():105420. PubMed ID: 34218062 [TBL] [Abstract][Full Text] [Related]
17. Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach. Merlano MC; Denaro N; Garrone O Curr Opin Oncol; 2020 May; 32(3):203-209. PubMed ID: 32195680 [TBL] [Abstract][Full Text] [Related]
18. Machine learning developed a macrophage signature for predicting prognosis, immune infiltration and immunotherapy features in head and neck squamous cell carcinoma. Wang Y; Mou YK; Liu WC; Wang HR; Song XY; Yang T; Ren C; Song XC Sci Rep; 2024 Aug; 14(1):19538. PubMed ID: 39174693 [TBL] [Abstract][Full Text] [Related]
19. FAT1 as a tumor mutation burden specific gene affects the immunotherapy effect in head and neck squamous cell cancer. Cao H; Lan T; Kuang S; Wang L; Li J; Li Q; Li Y; Xu Q; Chen Q; Ren S; Lan C; Ouyang N; Liao J; Huang Y; Li J Drug Resist Updat; 2024 Sep; 76():101095. PubMed ID: 38986165 [TBL] [Abstract][Full Text] [Related]
20. Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms. Wang G; Zhang M; Cheng M; Wang X; Li K; Chen J; Chen Z; Chen S; Chen J; Xiong G; Xu X; Wang C; Chen D Cancer Lett; 2021 Jun; 507():55-69. PubMed ID: 33741424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]